Education
About Us
Working with TipRanks
Follow Us
AbSci (ABSI)
NASDAQ:ABSI
Earnings Data
Report Date
May 20, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.22Last Year’s EPS
-0.22Same Quarter Last Year
Strong Buy
Based on 8 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 18, 2025
|% Change Since: -2.27%
|Next Earnings Date:May 20, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted Absci's achievements in advancing their AI drug creation platform and securing strategic partnerships, which contribute to their long-term potential. However, increased R&D expenses and decreased quarterly revenue suggest some immediate financial challenges. The sentiment is balanced given the strong future outlook offset by current financial metrics.Company Guidance
During the call, Absci provided guidance on several key metrics, emphasizing their progress and strategic outlook. They highlighted the addition of four new partners in 2024, achieving their partnership guidance for the year. The company is advancing its proprietary internal programs, including ABS-101 and ABS-201, with clinical trials for ABS-101 expected in the first half of 2025 and ABS-201 in early 2026. Financially, Absci reported a fourth-quarter revenue of $0.7 million, with research and development expenses reaching $18.4 million, primarily due to the advancement of internal programs. They ended the year with $112.4 million in cash and short-term investments, supplemented by a $20 million strategic investment from AMD and an additional $20 million raised from mutual funds. Absci expects their current cash reserves to fund operations into the first half of 2027. The company is also focusing on a potential large pharma partnership and anticipates signing one or more such collaborations in 2025.Successful Advancements in AI Drug Creation Platform
Absci demonstrated significant advancements in their AI integrated drug creation platform, including breakthroughs in de novo antibody design, particularly for creating a universal neutralizing HIV antibody, which was a collaboration with Caltech.
Strategic Partnerships and Collaborations
Absci added new partners like Owkin and Invetx, expanding their reach in AI-driven drug creation and animal health applications. Additionally, a strategic partnership with AMD included a $20 million investment to enhance computing capabilities.
Promising Pipeline Developments
Introduction of ABS-201, a potential best-in-class anti-prolactin receptor antibody for androgenic alopecia, and exciting preclinical data for ABS-101 and ABS-501, showcasing potential first-in-class and best-in-class attributes.
Financial Stability and Strategic Funding
Absci ended the year with $112.4 million in cash and investments, and raised an additional $40 million from strategic partnerships and mutual funds, extending their cash runway into the first half of 2027.
---
ABSI Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ABSI Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 18, 2025 | $3.08 | $2.98 | -3.25% |
| Nov 12, 2024 | $4.28 | $3.64 | -14.95% |
| Aug 14, 2024 | $3.73 | $4.14 | +10.99% |
| May 14, 2024 | $5.06 | $4.83 | -4.55% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does AbSci (ABSI) report earnings?
AbSci (ABSI) is schdueled to report earning on May 20, 2025, TBA Not Confirmed.
What is AbSci (ABSI) earnings time?
AbSci (ABSI) earnings time is at May 20, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ABSI EPS forecast?
ABSI EPS forecast for the fiscal quarter 2025 (Q1) is -0.22.
---